With the recognition of HER2-low BC as a distinct entity, there is now a critical need for a ternary classification of HER2 expression - overexpressed, low, and zero - to accurately triage new BC diagnoses for appropriate anti-HER2 therapies [11]. Here, ERBB2 is linked to breast cancer.